Patient Case Report : Memantine for the Treatment of Occipital Neuralgia
Occipital neuralgia (ON) is described as a shooting, stabbing pain in the posterior part of the scalp that involves the occipital nerve. The epidemiology and pathophysiology are uncertain, but ON is considered distinct from other headache types. At the time of this writing, memantine for the treatment of ON has not been described in the literature. The following details a case report of successful treatment of ON with memantine. A 64-year-old, 91-kg, White man presented with severe headache associated with ON. Previous trials of oral medications, acupuncture, or physical therapy did not provide relief. The patient reported 15 ON headache days per month, use of 18 sumatriptan tablets per month, and daily use of as-needed ibuprofen. Because of inadequate relief of ON from other treatments, memantine was started. After titration to memantine 10 mg by mouth twice daily, the patient reported he was "100% headache free" from his ON pain. The patient tolerated memantine well without adverse effects. This case report displays safe, effective, and novel treatment of ON with memantine 10 mg by mouth daily, twice daily. The known safety, tolerability, and pharmacodynamics of memantine may warrant its off-label use in future studies exploring efficacy in ON.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Clinical neuropharmacology - 43(2020), 6 vom: 01. Nov., Seite 198-200 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hayes, William J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.10.2021 Date Revised 12.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/WNF.0000000000000415 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315274492 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315274492 | ||
| 003 | DE-627 | ||
| 005 | 20231225154544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/WNF.0000000000000415 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315274492 | ||
| 035 | |a (NLM)32956140 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hayes, William J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient Case Report |b Memantine for the Treatment of Occipital Neuralgia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.10.2021 | ||
| 500 | |a Date Revised 12.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Occipital neuralgia (ON) is described as a shooting, stabbing pain in the posterior part of the scalp that involves the occipital nerve. The epidemiology and pathophysiology are uncertain, but ON is considered distinct from other headache types. At the time of this writing, memantine for the treatment of ON has not been described in the literature. The following details a case report of successful treatment of ON with memantine. A 64-year-old, 91-kg, White man presented with severe headache associated with ON. Previous trials of oral medications, acupuncture, or physical therapy did not provide relief. The patient reported 15 ON headache days per month, use of 18 sumatriptan tablets per month, and daily use of as-needed ibuprofen. Because of inadequate relief of ON from other treatments, memantine was started. After titration to memantine 10 mg by mouth twice daily, the patient reported he was "100% headache free" from his ON pain. The patient tolerated memantine well without adverse effects. This case report displays safe, effective, and novel treatment of ON with memantine 10 mg by mouth daily, twice daily. The known safety, tolerability, and pharmacodynamics of memantine may warrant its off-label use in future studies exploring efficacy in ON | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Memantine |2 NLM | |
| 650 | 7 | |a W8O17SJF3T |2 NLM | |
| 700 | 1 | |a Hoffmann, Chelsea |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobson, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Kotschevar, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Kappes, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Berendse, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical neuropharmacology |d 1993 |g 43(2020), 6 vom: 01. Nov., Seite 198-200 |w (DE-627)NLM013045784 |x 1537-162X |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:6 |g day:01 |g month:11 |g pages:198-200 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/WNF.0000000000000415 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 6 |b 01 |c 11 |h 198-200 | ||